LLY — ELI LILLY & Co
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 59478 ·
Last close
$1415.55
Market Cap
$1.26T
52W High
$1475.25
52W Low
$846.81
ADV30
2,818,485
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 24,397,000,000 | 20,464,000,000 | 13,092,000,000 | 6,451,000,000 | 148,072,000,000 | 4,885,000,000 | 107,801,000,000 |
| Jun 2026 | 22,974,000,000 | 19,706,000,000 | 12,457,000,000 | 7,095,000,000 | 142,283,000,000 | 8,950,000,000 | 108,404,000,000 |
| Mar 2026 | 19,799,000,000 | 16,222,000,000 | 9,778,000,000 | 7,396,000,000 | 116,576,000,000 | 5,282,000,000 | 85,378,000,000 |
| Dec 2025 | 19,292,000,000 | 15,920,300,000 | 8,987,400,000 | 6,637,700,000 | 112,476,000,000 | 7,268,000,000 | 85,941,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$30,644,600,000
Investing CF
$-30,413,200,000
Financing CF
$-5,141,800,000
CapEx
$-18,955,400,000
Dividends Paid
$-5,980,500,000
Buybacks
$-5,841,700,000
EPS Diluted TTM
$30.81
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$37,969,000,000
Inventory
$18,194,000,000
Receivables
$25,231,000,000
ST Investments
$121,600,000
EBIT TTM
$46,885,800,000
Pretax Income TTM
$34,769,200,000
Interest Exp TTM
$672,300,000
Analysts
29
Yahoo Snapshot (yfinance, live)
Total Revenue
$86,461,997,056
EBITDA
$46,489,001,984
Free Cash Flow
$9,343,699,968
Enterprise Value
$1,307,284,733,952
Total Cash
$4,885,000,192
Total Debt
$49,502,998,528
Shares Out
890,745,031
Trailing EPS
$30.81
Book Value
$45.19
ROE
86.0%
ROA
21.1%
Div Yield
0.49%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 65,179,000,000 | 29,696,000,000 | 20,640,000,000 | 112,476,000,000 | 85,941,000,000 | 26,535,000,000 | 16,813,000,000 |
| Dec 2024 | 45,043,000,000 | 17,040,000,000 | 10,590,000,000 | 78,715,000,000 | 64,443,000,000 | 14,272,000,000 | 8,818,000,000 |
| Dec 2023 | 34,124,000,000 | 10,325,000,000 | 5,240,000,000 | 64,006,300,000 | 53,142,600,000 | 10,771,900,000 | 4,240,000,000 |
| Dec 2022 | 28,541,400,000 | 8,280,400,000 | 6,244,800,000 | 49,489,800,000 | 38,714,400,000 | 10,649,800,000 | 7,585,700,000 |
TTM Snapshot
Revenues TTM
$79,665,800,000
NetIncome TTM
$26,711,200,000
OpCashFlow TTM
—
Assets (Latest)
$142,283,000,000
Forward EPS
$49.46
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1400.00 · spot: $1382.75 · call volume: 2,799 · put volume: 3,810
Expected Move to 2026-12-18:
±$108.00
(7.81%) —
implied range
$1274.75 –
$1490.75
· ATM straddle on $1380.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
| AZN | ASTRAZENECA PLC | $282.68B | $182.27 | — |
News headlines (Yahoo Finance, 1h cache)
Lilly Buying Spree Surpasses $32B
2026-11-18 21:13 · Yahoo
Health Canada approves Lilly's Mounjaro® (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
2026-11-18 18:00 · Yahoo
VitriVax Announces $87 Million Series C Financing to Advance Lyme Disease Vaccine Candidate into the Clinic and Expand Pipeline
2026-11-18 17:45 · Yahoo
Is Lilly Stock's Winning Streak Skill Or Luck?
2026-11-18 15:07 · Yahoo
48 ETFs Add to Lilly (LLY) Holdings on Nov. 16
2026-11-18 11:02 · Yahoo
Eli Lilly Is Up 39% in a Year. Barclays Sees Another 9%
2026-11-17 22:53 · Yahoo
Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
2026-11-17 21:37 · Yahoo
Third-Party Vendor Linked to Eli Lilly Is Hit by Data Breach
2026-11-17 20:02 · Yahoo
Positive Trial Results Could Be A Big Moment For Eli Lilly Stock
2026-11-17 19:11 · Yahoo
Eli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio
2026-11-17 17:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.